Hey Doc,
here is my answer to your question and take on the current situation.
A friend of my recently contacted Todd Falls, and he forwarded me Todd's reply.
As usual his response was very upbeat and positive. Stating that they would be able to discuss corporate actions within the next days or weeks
(he used the following exact word "My hope & expectations are we will be able to discuss corporate actions shortly. But is shortly tomorrow – next week – 3 weeks - more??? That I don’t know ..."
, and that Joe and his management team want nothing more than to update shareholders on all that is going on, and the progress that was made during the last couple of months. As soon as that would be possible, it will be the first thing that they are going to do.
He also emphasized that since the Corona pandemic hit all of us, GNBT as a corporation had (quote from his letter) "several significant issues to deal with".
He also added at the very end, that they are deliberately working on all the things necessary for the NGIO IPO to move forward.
With that said, here is what I expect:
1) We will receive a general update on all things GNBT and its subs.
Result: The lid is opened in front of our eyes, and we all can see that "Schroedinger's cat is still alive and very much kicking"
==> share price will increase significantly, just because GNBT's market capitalisation currently is that of a company that is going out of business. With the proof that this is not the case, the PPS will significantly increase again.
2) We will learn from that PR that Olaregen has received loan based funding to ramp up production for Excellegan, and that they are about to sell first batches and will soon be producing significant revenues. ==> share price will increase
3) Significant progress has been made as well in regards to the "Complete Vaccine". Let's say they have been able to get their IND application approved and were able to get Phase I clinical trials already setup. ==> GNBT PPS to increase on these news, as well as important milestone information in regards to the NGIO IPO.
4) A clear schedule for an NGIO IPO to still happen in 2021.
After a first PR, which should incluse updates on at least 1-4) I can imagine that the PPS would jump directly to - maybe - $.50/share on the day that it is going to be released.
In the days to follow I can easily see it going up to $1/share.
As the NGIO IPO gets closer and closer, I can imagine that we can actually reach at least $2/share, if not the previous highs of > $3/share.
With a conservative evaluation of NGIO of $500 mill., and in addtion Excellagen sales already creating or soon to be creating significant cash flow, I still think that GNBT being valued at $360 million ($3/sh * 120 mill GNBT share OS) a total bargain value.
So yeah, I cannot wait for that PR to finally be released and the GNBT pps to rise back up like a phoenix from the ashes. I still very much believe that this is possible, and that email message from Todd that I was made aware of, is just another factor that hightens my optimism in this regard.
here is my answer to your question and take on the current situation.
A friend of my recently contacted Todd Falls, and he forwarded me Todd's reply.
As usual his response was very upbeat and positive. Stating that they would be able to discuss corporate actions within the next days or weeks
(he used the following exact word "My hope & expectations are we will be able to discuss corporate actions shortly. But is shortly tomorrow – next week – 3 weeks - more??? That I don’t know ..."
, and that Joe and his management team want nothing more than to update shareholders on all that is going on, and the progress that was made during the last couple of months. As soon as that would be possible, it will be the first thing that they are going to do.
He also emphasized that since the Corona pandemic hit all of us, GNBT as a corporation had (quote from his letter) "several significant issues to deal with".
He also added at the very end, that they are deliberately working on all the things necessary for the NGIO IPO to move forward.
With that said, here is what I expect:
1) We will receive a general update on all things GNBT and its subs.
Result: The lid is opened in front of our eyes, and we all can see that "Schroedinger's cat is still alive and very much kicking"
==> share price will increase significantly, just because GNBT's market capitalisation currently is that of a company that is going out of business. With the proof that this is not the case, the PPS will significantly increase again.
2) We will learn from that PR that Olaregen has received loan based funding to ramp up production for Excellegan, and that they are about to sell first batches and will soon be producing significant revenues. ==> share price will increase
3) Significant progress has been made as well in regards to the "Complete Vaccine". Let's say they have been able to get their IND application approved and were able to get Phase I clinical trials already setup. ==> GNBT PPS to increase on these news, as well as important milestone information in regards to the NGIO IPO.
4) A clear schedule for an NGIO IPO to still happen in 2021.
After a first PR, which should incluse updates on at least 1-4) I can imagine that the PPS would jump directly to - maybe - $.50/share on the day that it is going to be released.
In the days to follow I can easily see it going up to $1/share.
As the NGIO IPO gets closer and closer, I can imagine that we can actually reach at least $2/share, if not the previous highs of > $3/share.
With a conservative evaluation of NGIO of $500 mill., and in addtion Excellagen sales already creating or soon to be creating significant cash flow, I still think that GNBT being valued at $360 million ($3/sh * 120 mill GNBT share OS) a total bargain value.
So yeah, I cannot wait for that PR to finally be released and the GNBT pps to rise back up like a phoenix from the ashes. I still very much believe that this is possible, and that email message from Todd that I was made aware of, is just another factor that hightens my optimism in this regard.
4
